阿武美替尼联合或单用地法替尼治疗复发性低级别浆液性卵巢癌的疗效与安全性:ENGOT-OV60/GOG-3052/RAMP 201 主要分析
这项 II 期开放标签研究评估了阿武美替尼单药或联合地法替尼治疗复发性低级别浆液性卵巢癌(LGSOC)的疗效与安全性。115 例患者接受联合方案,确认的客观缓解率(ORR)为 31%(95%CI 23% 至 41%),KRAS 突变型为 44%、野生型为 17%;中位无进展生存期总体为 12.9 个月。作者认为该联合方案的疗效与安全性支持其作为复发性 LGSOC 的潜在标准治疗。
要点
- 联合方案确认的 ORR 为 31%(95%CI 23% 至 41%),KRAS 突变型 44%、野生型 17%。
- 总体中位无进展生存期 12.9 个月,KRAS 突变型 22.0 个月、野生型 12.8 个月。
- 最常见 ≥3 级治疗相关不良事件为肌酸磷酸激酶升高(24%)、腹泻(8%)和贫血(5%)。
核心结论
- 阿武美替尼联合地法替尼的疗效与安全性支持该联合方案作为复发性 LGSOC 的潜在标准治疗。
- 一项阿武美替尼联合地法替尼对比研究者选择治疗的随机 III 期研究正在招募复发性 LGSOC 女性患者(RAMP301;ClinicalTrials.gov 标识符:NCT06072781)。
研究设计与样本
- II 期开放标签研究,纳入既往接受过 ≥1 线铂类化疗后复发、可测量 LGSOC 的患者。
- 患者按肿瘤 KRAS 突变状态分层,随机分配至口服阿武美替尼 4.0 mg 每周两次单药,或阿武美替尼 3.2 mg 每周两次联合口服地法替尼 200 mg 每日两次。
- 联合方案被选为扩展的后续方案;主要终点为盲法独立中心审查的客观缓解率(ORR)。
- 共 115 例患者接受了后续联合方案。
主要发现
- 患者既往治疗中位线数为 3 线(范围 1-9),包括内分泌治疗(86%)、贝伐珠单抗(51%)和 MEK 抑制剂(22%)。
- 确认的 ORR 为 31%(95%CI 23% 至 41%),中位缓解持续时间为 31.1 个月(95%CI 14.8 至 31.1)。
- ORR 在 KRAS 突变型队列为 44%,在 KRAS 野生型队列为 17%。
- 中位无进展生存期总体为 12.9 个月(95%CI 10.9 至 20.2),KRAS 突变型队列为 22.0 个月(95%CI 11.1 至 36.6),KRAS 野生型队列为 12.8 个月(95%CI 7.4 至 18.4)。
- 最常见的 ≥3 级治疗相关不良事件为肌酸磷酸激酶升高(24%)、腹泻(8%)和贫血(5%);10% 的患者因不良事件停药。
临床怎么用
- 作者认为,阿武美替尼联合地法替尼的疗效与安全性支持该联合方案作为复发性 LGSOC 的潜在标准治疗。
- 阿武美替尼联合地法替尼对比研究者选择治疗的随机 III 期研究正在招募复发性 LGSOC 女性患者(RAMP301;NCT06072781)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal adhesion kinase inhibitor) in patients with recurrent low-grade serous ovarian cancer (LGSOC). METHODS: In this phase II, open-label study, patients with recurrent, measurable LGSOC after ≥1 line of platinum chemotherapy were stratified by tumor Kirsten rat sarcoma virus homolog (KRAS) mutation status and randomly assigned to oral avutometinib 4.0 mg two times per week monotherapy or avutometinib 3.2 mg two times per week in combination with oral defactinib 200 mg two times per day. The combination was selected as the go-forward regimen for expansion. The primary end point was objective response rate (ORR) by blinded independent central review. RESULTS: A total of 115 patients received the go-forward combination regimen. Patients had a median of 3 (range, 1-9) prior lines of therapy, including hormonal (86%), bevacizumab (51%), and MEK inhibitor (22%). Confirmed ORR was 31% (95% CI, 23% to 41%) with a median duration of response of 31.1 months (95% CI, 14.8 to 31.1). ORR was 44% in KRAS-mutant and 17% in KRAS wild-type cohorts. The median progression-free survival was 12.9 months (95% CI, 10.9 to 20.2) overall and 22.0 months (95% CI, 11.1 to 36.6) and 12.8 months (95% CI, 7.4 to 18.4) in KRAS-mutant and wild-type cohorts, respectively. The most frequent grade ≥3 treatment-related adverse events (AEs) were elevated creatine phosphokinase (24%), diarrhea (8%), and anemia (5%). Ten percent of patients discontinued because of AEs. CONCLUSION: The efficacy and safety profile of avutometinib in combination with defactinib support this combination as a potential standard of care for recurrent LGSOC. A randomized phase 3 study of avutometinib and defactinib versus investigator's choice of therapy for women with recurrent LGSOC is currently enrolling (RAMP301; ClinicalTrials.gov identifier: NCT06072781).
引用
- Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025. PMID: 40644648. doi:10.1200/JCO-25-00112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。